The CVD Model, and its Scenarios
The CVD Model
This document describes the CVD state-transition model, and the scenarios which are run using it.
Model Structure
CVD Models creates several scenarios: cvd_null, CV1, CV2a, CV2b, CV3, CV4a, CV4b, CV6 and CV7
The CVD Model refers to a "Model architecture": A structure of states and transitions, which can be used to run different scenarios. A scenario is when the structure has a different set of transition rates between the states.
The CVD model is used to run several scenarios of treatment coverage: CV1, CV2a, CV2b, CV3, CV4a, CV4b, CV6 and CV7. NOTE - CV5a and CV5b relate to Rheumatic Heart Disease, and rely on a separate disease model. In addition, the CVD model is also used to run a "Null Scenario": Called cvd_null. We will explain the Null Scenario later.
Structure of the CVD Model
CVD has several key states, DsFreeSus, IHDAcute, StrokeAcute, IHDPostAcute, StrokePostAcute, StrokeIHDPostAcute and Deceased
DsFreeSus means "Disease free, susceptible", and this refers to the majority of the population.
IHD refers to Ischaemic Heart Disease, and is generally referring to the process of an acute myocardial infarction (AMI)
Deceased refers to the people in the model who have died, either through background mortality (DsFreeSus -> Deceased) or through the CVD episode (cvdEpsd -> Deceased).
In general, people are Disease Free, but may have an Acute Myocardial Infarction (IHDAcute) or a stroke (StrokeAcute).
After these events, people move to being PostAcute and end in the state StrokeIHDPostAcute, which collects both groups of persons.
There is no recovery from any of these states, so once someone has had an AMI or Stroke, they will progress irreversibly to StrokeIHDPostAcute.
Treatments (described below) work by reducing the mortality of IHDAcute or StrokeAcute. For example, if someone has a stroke (i.e. moves to StrokeAcute), and they receive aspirin (TreatStrokeAcuteAspirin), this may reduce their mortality. If they survive, they will move to StrokePostAcute
In addition to these states, there are other "states" which are used to perform calculations, or collect useful statistics about the model.
This is something we have chosen to do in our model structure, so it's visible to users, but it is not strictly necessary.
For example, we have states for Disability, which collects information about the stock of key states and multiplies them against some disability weight.
We also have states to calculate births, migration, and the effects of interventions on disability and mortality.
Once again, we made these design decisions so that users can see how these work, but they aren't strictly necessary.
They can be done elsewhere, and simply rendered as a transition rate.
The Model has two key components
The main component moves people between states
The main component has the states we've introduced: DsFreeSus, IHDAcute, IHDPostAcute, StrokeAcute, StrokePostAcute, StrokeIHDPostAcute, Deceased, Disability, Births.
Importantly there are some other states which sit between states:
DsFreeSus Disabilitysits betweenDsFreeSusandDisabilityIHDAcute Disabilitysits betweenIHDAcuteandDisabilityIHDPostAcute Disabilitysits betweenIHDPostAcuteandDisabilityStrokeAcute Disabilitysits betweenStrokeAcuteandDisabilityStrokePostAcute Disabilitysits betweenStrokePostAcuteandDisabilityStrokeIHDPostAcute Disabilitysits betweenStrokeIHDPostAcuteandDisabilityIHDAcute Mortalitysits betweenIHDAcuteandMortalityIHDPostAcute Mortalitysits betweenIHDPostAcuteandMortalityStrokeAcute Mortalitysits betweenStrokeAcuteandMortalityStrokePostAcute Mortalitysits betweenStrokePostAcuteandMortalityStrokeIHDPostAcute Mortalitysits betweenStrokeIHDPostAcuteandMortality
These states aren't really states in a true sense.
Rather, these states set the value of the transition rates around them.
So, for example, DsFreeSus Disability is really the transition rate for DsFreeSus -> Disability.
In the nomenclature of the Botech protocol, we call this a "Surrogate node".
This is a structural decision we have made, but it doesn't change the results.
Rather, we do this, so we can show how the calculations work to determine the disability and mortality effects.
The calculation component sets the transition rates
The "Surrogate Nodes" mentioned above, are set by a series of calculations in the model. These calculations follow the common order of operations described in the introduction.
Order of Operations
The CVD model follows the common order of operations used by all disease models. The key CVD-specific variations are:
Treatment Effect Calculations (Steps 4-7)
CVD has eight acute treatments for stroke and myocardial infarction events, each with specific mortality impacts.
Step 4 example: TreatAMIAcuteAspirin_PIN × TreatAMIAcuteAspirin_Mortality_Impact × TreatAMIAcuteAspirin_Calculated_Coverage
Step 6: Blended disability calculated for multiple states: StrokeAcute, StrokePostAcute, IHDAcute, IHDPostAcute, and StrokeIHDPostAcute
Main State Transitions (Step 10)
CVD has a more complex state progression:
DsFreeSus → StrokeAcuteorIHDAcute(acute events)StrokeAcute → StrokePostAcuteandIHDAcute → IHDPostAcute(survival)StrokePostAcute, IHDPostAcute → StrokeIHDPostAcute(combined post-acute state)- Various mortality pathways throughout the progression
Interventions
Intervention Overview Table
| Category | Code | Name |
|---|---|---|
| Cardiovascular diseases | CV1 | Pharmacological treatment of hypertension in adults using either of the following: ACE-I; ARB; CCB. Single pill combination containing either of the following: ACE-I/CCB; ACE-I/Diuretic; ARB/CCB; ARB/Diuretic |
| Cardiovascular diseases | CV2a | Drug therapy to control CVD risk using a total risk* approach and counselling to individuals who have had a heart attack or stroke and to persons with high risk (≥ 20%) of a fatal and non-fatal cardiovascular event in the next 10 years using the updated WHO CVD risk charts |
| Cardiovascular diseases | CV2b | Drug therapy to control CVD risk using a total risk* approach and counselling to individuals who have had a heart attack or stroke and to persons with high risk (≥ 10%) of a fatal and non-fatal cardiovascular event in the next 10 years using the updated WHO CVD risk charts |
| Cardiovascular diseases | CV3a | Treatment new cases of acute myocardial infarction with aspirin, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate |
| Cardiovascular diseases | CV3b | Treatment of new cases of acute myocardial infarction with aspirin and thrombolysis, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate |
| Cardiovascular diseases | CV3c | Treatment new cases of acute myocardial infarction with thrombolysis, aspirin and clopidogrel, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate |
| Cardiovascular diseases | CV3d | Treatment of new cases of myocardial infarction with primary percutaneous coronary interventions (PCI), aspirin and clopidogrel, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate |
| Cardiovascular diseases | CV4a | Treatment of acute ischemic stroke with intravenous thrombolytic therapy |
| Cardiovascular diseases | CV4b | Treatment of acute ischemic stroke with mechanical thrombectomy within an experienced facility |
| Cardiovascular diseases | CV5a | Primary prevention of rheumatic fever and rheumatic heart diseases by increasing appropriate treatment of streptococcal pharyngitis at the primary care level |
| Cardiovascular diseases | CV5b | Secondary prevention of rheumatic fever and rheumatic heart disease by developing a register of patients who receive regular prophylactic penicillin |
| Cardiovascular diseases | CV6 | Low-dose acetylsalicylic acid within 24 to 48 hours for secondary prevention of ischemic stroke |
| Cardiovascular diseases | CV7 | Comprehensive care of acute stroke patients in stroke units |
| Cardiovascular diseases | Treatment of congestive cardiac failure with angiotensin-converting-enzyme inhibitor, beta-blocker and diuretic | |
| Cardiovascular diseases | Cardiac rehabilitation post myocardial infarction | |
| Cardiovascular diseases | Anticoagulation for medium-and high-risk non-valvular atrial fibrillation and for mitral stenosis with atrial fibrillation |
The modelled treatments and their assumptions
For CVD, there are eight treatments, which are referenced in the table below. This table also lists the reference name in the model, and in which scenario the treatment is scaled up. Furthermore, the PIN (population in need) and the impact is listed.
| Intervention | Reference | Scenario | PIN | Source | Target | Impact |
|---|---|---|---|---|---|---|
| Treatment of acute AMI with aspirin | TreatAMIAcuteAspirin | CV3a | 0.3 | IHDAcute | Deceased | -0.25 |
| Treatment of acute AMI with aspirin and thrombolysis | TreatAMIAcuteAspirinAndTrombolysis | CV3b | 0.3 | IHDAcute | Deceased | -0.43 |
| Treatment of acute AMI with thrombolysis, aspirin and clopidogrel | TreatAMIAcuteAspirinAndClopidro | CV3c | 0.3 | IHDAcute | Deceased | -0.52 |
| Treatment of acute AMI with PCI, aspirin and clopidogrel | TreatAMIAcutePCIAndAspirinAndClopidro | CV3d | 0.1 | IHDAcute | Deceased | -0.74 |
| Treatment of acute ischaemic stroke with mechanical thrombectomy | TreatMechanicalTrombStroke | CV4b | 0.15 | StrokeAcute | Deceased | -0.15 |
| Treatment of acute ischaemic stroke with intravenous thrombolytic | TreatIntravTrombStroke | CV4a | 0.35 | StrokeAcute | Deceased | -0.34 |
| Treatment of acute stroke with aspirin | TreatStrokeAcuteAspirin | CV6 | 1 | StrokeAcute | Deceased | -0.05 |
| Comprehensive care for acute stroke | TreatStrokeCare | 1 | StrokeAcute | Deceased | -0.20 |
CV1
| Label | Baseline | Target |
|---|---|---|
| Without diabetes, Treatment BP, SBP > 140 mmHg | 5 | 95 |
CV2a
| Label | Baseline | Target |
|---|---|---|
| Without diabetes, Treatment BP, TR > 20%, SBP > 130 mmHg | 5 | 95 |
CV2b
| Label | Baseline | Target |
|---|---|---|
| Without diabetes, Treatment BP, TR 10-20%, SBP > 140 mmHg | 5 | 95 |
| Without diabetes, Treatment BP, TR > 20%, SBP > 130 mmHg | 5 | 95 |
CV3a
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute AMI with aspirin | 5 | 95 |
CV3b
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute AMI with aspirin and thrombolysis | 5 | 95 |
CV3c
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute AMI with thrombolysis, aspirin, and clopidogrel | 5 | 95 |
CV3d
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute AMI with PCI, aspirin, and clopidogrel | 5 | 95 |
CV4a
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute ischemic stroke with intravenous thrombolytic therapy | 5 | 95 |
CV4b
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute ischemic stroke with mechanical thrombectomy | 5 | 95 |
CV6
| Label | Baseline | Target |
|---|---|---|
| Treatment of acute stroke with aspirin | 5 | 95 |
CV7
| Label | Baseline | Target |
|---|---|---|
| Comprehensive care for acute stroke | 5 | 95 |